Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Irinotecan vs non‐irinotecan‐containing regimens

Progression‐free survival (PSF) · people with advanced gastric cancer

Irinotecan probably leads to lower progression‐free survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.51 [0.33, 0.77]
1 study · 90 participants
Moderate